Home › Funds › HEIGHTS CAPITAL MANAGEMENT, INC › CABA
HEIGHTS CAPITAL MANAGEMENT, INC position in CABA
CABALETTA BIO INC · Health Care
HEIGHTS CAPITAL MANAGEMENT, INC reported holding 2,500,000 shares of CABA (CABALETTA BIO INC) in its Q3 2026 13F filing — a position valued at US$4.8M, representing 1.19% of its reported portfolio and ranking #18 among its reported holdings. HEIGHTS CAPITAL MANAGEMENT, INC has disclosed CABA holdings in 4 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How HEIGHTS CAPITAL MANAGEMENT, INC's CABA position evolved
HEIGHTS CAPITAL MANAGEMENT, INC first disclosed a stake in CABA in Q2 2025 at 3,144,106 shares (US$4.8M). The position peaked in Q3 2025 at 2,084,202 shares, worth US$4.9M. Across 4 filings, HEIGHTS CAPITAL MANAGEMENT, INC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,500,000 shares valued at US$4.8M — an increase of 1,744,374 shares quarter over quarter.. Notable position changes include a 34% trim in Q3 2025 (shares fell 6% over the following quarter), a 231% increase in Q3 2026 (shares fell 42% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 3.14M | $4.78M | New |
| Q3 2025 | 2.08M | $4.88M | Reduce |
| Q2 2026 | 755.63K | $2.35M | New |
| Q3 2026 | 2.50M | $4.80M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CABA and 13F data
CABA (CABALETTA BIO INC) is a Health Care company. 29 other funds we track also report a position in CABA — the largest reported positions include Bain Capital Life Sciences Investors, LLC (US$40.7M), Opaleye Management Inc. (US$12.0M), Cormorant Asset Management, LP (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CABA
- Bain Capital Life Sciences Investors, LLC 21.21M sh · $40.72M · Q3 2026
- Opaleye Management Inc. 3.86M sh · $12.02M · Q2 2026
- Cormorant Asset Management, LP 4.50M sh · $8.64M · Q3 2026
- Propel Bio Management, LLC 2.05M sh · $3.93M · Q3 2026
- Diametric Capital, LP 1.87M sh · $3.60M · Q3 2026
More on HEIGHTS CAPITAL MANAGEMENT, INC
FAQ
How long has HEIGHTS CAPITAL MANAGEMENT, INC held CABA?
HEIGHTS CAPITAL MANAGEMENT, INC has disclosed CABA holdings in 4 of the last 6 reported quarters, going back to Q2 2025.
What is HEIGHTS CAPITAL MANAGEMENT, INC's current position in CABA?
As of Q3 2026, HEIGHTS CAPITAL MANAGEMENT, INC holds 2.50M shares of CABA (CABALETTA BIO INC), valued at $4.80M, representing 1.19% of its reported portfolio and ranking #18.
Has HEIGHTS CAPITAL MANAGEMENT, INC been buying or selling CABA?
In the latest 13F filing (Q3 2026), HEIGHTS CAPITAL MANAGEMENT, INC increased its position in CABA. The position peaked in Q3 2025 at 2.08M shares.
Which other funds hold CABA?
Other major institutional holders of CABA include Bain Capital Life Sciences Investors, LLC, Opaleye Management Inc., Cormorant Asset Management, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.